Warning: The NCBI web site requires JavaScript to function. more...
Proteolysis Research Group, School of Biochemistry and Molecular Biology, University of Leeds, LS2 9JT, Leeds, UK. a.j.turner@leeds.ac.uk
Modulation of the renin-angiotensin system (RAS), and particularly inhibition of angiotensin-converting enzyme (ACE), a zinc metallopeptidase, has long been a prime strategy in the treatment of hypertension. However, other angiotensin metabolites are gaining in importance as our understanding of the RAS increases. Recently, genomic approaches have identified the first human homologue of ACE, termed ACEH (or ACE2). ACEH differs in specificity and physiological roles from ACE, which opens a potential new area for discovery biology. The gene that encodes collectrin, a homologue of ACEH, is upregulated in response to renal injury. Collectrin lacks a catalytic domain, which indicates that there is more to ACE-like function than simple peptide hydrolysis.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on